Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP2C9 | P11712 | 1/20 | 0.55 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.55 |
| ▸ | XDH | P47989 | 3/20 | 0.47 |
| ▸ | CYP11B1 | P15538 | 2/20 | 0.46 |
| ▸ | CYP11B2 | P19099 | 2/20 | 0.46 |
| ▸ | PFKFB3 | Q16875 | 1/20 | 0.44 |
| ▸ | P2RY12 | Q9H244 | 1/20 | 0.44 |
| ▸ | PDGFRB | P09619 | 1/20 | 0.44 |
| ▸ | PDGFRA | P16234 | 1/20 | 0.44 |
| ▸ | MKNK1 | Q9BUB5 | 1/20 | 0.43 |
| ▸ | MKNK2 | Q9HBH9 | 1/20 | 0.43 |
| ▸ | LMNA | P02545 | 1/20 | 0.42 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.42 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.42 |
| ▸ | MAOA | P21397 | 1/20 | 0.42 |
| ▸ | SCN10A | Q9Y5Y9 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4901704 | 0.89 | PFKFB3 (0.45) | PFKFB3 | |
| SCHEMBL4908272 | 0.86 | LMNA (0.59) | CYP2C9CYP2C19CYP11B1CYP11B2PDGFRB | |
| SCHEMBL640338 | 0.85 | CYP2C9 (0.59) | CYP2C9CYP2C19XDHCYP11B1CYP11B2 | |
| SCHEMBL8622944 | 0.83 | CYP2C19 (0.57) | CYP2C9CYP2C19CYP1A2CYP3A4 | |
| SCHEMBL5372083 | 0.83 | CYP2C9 (0.65) | CYP2C9CYP2C19MKNK1MKNK2LMNA | |
| SCHEMBL13547445 | 0.83 | CYP2C19 (0.64) | CYP2C9CYP2C19CYP11B1CYP11B2P2RY12 | |
| SCHEMBL640295 | 0.82 | CYP11B1 (0.60) | CYP2C9CYP2C19CYP11B1CYP11B2PDGFRB | |
| SCHEMBL640303 | 0.80 | MAOB (0.54) | CYP2C9CYP2C19CYP11B1CYP11B2PDGFRB | |
| SCHEMBL1580240 | 0.79 | MKNK1 (0.42) | XDHCYP11B1CYP11B2MKNK1MKNK2 | |
| SCHEMBL4907523 | 0.79 | MAOB (0.54) | CYP2C9CYP2C19 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120214788-A1 | HETEROARYL-SUBSTITUTED PIPERIDINES | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2012-08-23 | — | — | US | disclosed |
| US-20120214788-A1 | HETEROARYL-SUBSTITUTED PIPERIDINES | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2012-08-23 | — | — | US | disclosed |
| US-20120214788-A1 | HETEROARYL-SUBSTITUTED PIPERIDINES | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2012-08-23 | — | — | US | disclosed |
| US-8119663-B2 | Heteroaryl-substituted piperidines | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2012-02-21 | — | — | US | disclosed |
| US-8119663-B2 | Heteroaryl-substituted piperidines | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2012-02-21 | — | — | US | disclosed |
| US-8119663-B2 | Heteroaryl-substituted piperidines | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2012-02-21 | — | — | US | disclosed |
| EP-2227466-B1 | HETEROARYL-SUBSTITUTED PIPERIDINES | BAYER SCHERING PHARMA AG (DE) | 2011-04-20 | — | — | EP | disclosed |
| US-20090306139-A1 | HETEROARYL-SUBSTITUTED PIPERIDINES | BAYER HEALTHCARE AG (DE) | 2009-12-10 | — | — | US | disclosed |
| US-20090306139-A1 | HETEROARYL-SUBSTITUTED PIPERIDINES | BAYER HEALTHCARE AG (DE) | 2009-12-10 | — | — | US | disclosed |
| US-20090306139-A1 | HETEROARYL-SUBSTITUTED PIPERIDINES | BAYER HEALTHCARE AG (DE) | 2009-12-10 | — | — | US | disclosed |
| WO-2009068214-A2 | HETEROARYL-SUBSTITUTED PIPERIDINES | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2009-06-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090306139-A1 | HETEROARYL-SUBSTITUTED PIPERIDINES | VHL, PIGO, PLIN3 | CYP2C9 1281/4885CYP2C19 618/4885XDH 1697/4885 |
| US-20120214788-A1 | HETEROARYL-SUBSTITUTED PIPERIDINES | VHL, PIGO, PLIN3 | CYP2C9 1281/4885CYP2C19 618/4885XDH 1697/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.